OUR 

VALUES

People

The CAPNOS mission is to help one million people quit vaping by 2027. We focus on the unique need for oral fixation cravings and stress relief alternatives to deliver a satisfying experience for anyone, anytime, anywhere.

Product

We specialize in producing affordable, accessible behavioral aids that can be used by youth and adults. Our products are not vapes, nor tobacco products, as only air is inhaled, yet can be used for quitting, stimming, or relief.

Planet

Our products are made to last, saving you money and reducing waste from offsetting the use of disposable products. We aim to help people live healthier lives, with a cleaner planet too.

Timeline

Our Impact

CAPNOS has delivered over 80,000 devices in the first three years of sales to customers in 93 countries and growing. Our team spans six continents, bringing a global perspective on a universal issue. We give back to local communities with free educational programming in schools, mentorship opportunities, and philanthropic donations supporting marginalized communities. CAPNOS is a certified LGBTQ+ and Asian-American-owned business.

Efforts to increase accessibility through retail adoption, partnerships with quit programs, and achieving operational excellency to provide lower costs with faster service is what compels us to seek constant improvement.  

Our Philosophy

Over one billion people smoke cigarettes globally. This habit is the leading cause for millions of preventable deaths yearly. Vaping was then positioned as a tool to reduce or quit smoking, having brought new pros and cons toward public health efforts. What then, could be used to help people quit vaping?

CAPNOS aims to educate and increase research interest in the field of sensory dependencies, as our devices are flavored, pressurized air inhalers for use as behavioral aids. We understand that the root craving often extends beyond nicotine, as shown by our CAPNOS Vaping Study Survey, published July 2024. 

Many people depend on vaping or smoking as a coping mechanism for stress or anxiety, to which an addiction often develops. We aim to further assess the efficacy of which CAPNOS devices can suppport habit reduction, replacement, or elimination efforts with vapes, through grant-funded research opportunities. Regulatory advocacy efforts are ongoing as we define a new product category that is neither a tobacco, nicotine, medical, or food item.

Academic research through laboratory studies are ongoing; we embrace challenging the status quo.

Brendan Wang

Founder and CEO

Edin Mucic

Brand Development Specialist

Pierre Aguilar

Community Development Specialist

Loretta Imonikhe

Human Resources and Administrative Associate

Martkim Salvador 

Customer Success Specialist